121 related articles for article (PubMed ID: 21680048)
1. Phase II study of sunitinib as maintenance therapy in patients with locally advanced or metastatic non-small cell lung cancer.
Gervais R; Hainsworth JD; Blais N; Besse B; Laskin J; Hamm JT; Lipton A; Albain KS; Masters GA; Natale RB; Selaru P; Kim ST; Chao RC; Page RD
Lung Cancer; 2011 Dec; 74(3):474-80. PubMed ID: 21680048
[TBL] [Abstract][Full Text] [Related]
2. Phase II study of maintenance sunitinib following irinotecan and carboplatin as first-line treatment for patients with extensive-stage small-cell lung cancer.
Spigel DR; Greco FA; Rubin MS; Shipley D; Thompson DS; Lubiner ET; Eakle JF; Quinn R; Burris HA; Hainsworth JD
Lung Cancer; 2012 Aug; 77(2):359-64. PubMed ID: 22560921
[TBL] [Abstract][Full Text] [Related]
3. Safety and efficacy of combining sunitinib with bevacizumab + paclitaxel/carboplatin in non-small cell lung cancer.
Socinski MA; Scappaticci FA; Samant M; Kolb MM; Kozloff MF
J Thorac Oncol; 2010 Mar; 5(3):354-60. PubMed ID: 20032789
[TBL] [Abstract][Full Text] [Related]
4. Maintenance Sunitinib following Initial Platinum-Based Combination Chemotherapy in Advanced-Stage IIIB/IV Non-Small Cell Lung Cancer: A Randomized, Double-Blind, Placebo-Controlled Phase III Study-CALGB 30607 (Alliance).
Baggstrom MQ; Socinski MA; Wang XF; Gu L; Stinchcombe TE; Edelman MJ; Baker S; Feliciano J; Novotny P; Hahn O; Crawford JA; Vokes EE
J Thorac Oncol; 2017 May; 12(5):843-849. PubMed ID: 28161554
[TBL] [Abstract][Full Text] [Related]
5. A randomized phase III trial of combined paclitaxel, carboplatin, and radiation therapy followed by weekly paclitaxel or observation for patients with locally advanced inoperable non-small-cell lung cancer.
Carter DL; Garfield D; Hathorn J; Mundis R; Boehm KA; Ilegbodu D; Asmar L; Reynolds C
Clin Lung Cancer; 2012 May; 13(3):205-13. PubMed ID: 22138037
[TBL] [Abstract][Full Text] [Related]
6. A phase I evaluation of oral CI-1033 in combination with paclitaxel and carboplatin as first-line chemotherapy in patients with advanced non-small cell lung cancer.
Chiappori AA; Ellis PM; Hamm JT; Bitran JD; Eiseman I; Lovalvo J; Burnett D; Olson S; Lenehan P; Zinner RG
J Thorac Oncol; 2006 Nov; 1(9):1010-9. PubMed ID: 17409987
[TBL] [Abstract][Full Text] [Related]
7. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 2.
Herbst RS; Giaccone G; Schiller JH; Natale RB; Miller V; Manegold C; Scagliotti G; Rosell R; Oliff I; Reeves JA; Wolf MK; Krebs AD; Averbuch SD; Ochs JS; Grous J; Fandi A; Johnson DH
J Clin Oncol; 2004 Mar; 22(5):785-94. PubMed ID: 14990633
[TBL] [Abstract][Full Text] [Related]
8. The current status and evolving role of sunitinib in non-small cell lung cancer.
Socinski MA
J Thorac Oncol; 2008 Jun; 3(6 Suppl 2):S119-23. PubMed ID: 18520293
[TBL] [Abstract][Full Text] [Related]
9. A phase II study of combination chemotherapy with docetaxel and carboplatin for elderly patients with advanced non-small cell lung cancer.
Kim HJ; Kim TG; Lee HJ; Kim JH; Lim BH; Seo JW; Kang EM; Lee BU; Ahn YM; Roh YH; Nam SH; Kim BS
Lung Cancer; 2010 May; 68(2):248-52. PubMed ID: 19647333
[TBL] [Abstract][Full Text] [Related]
10. Chemotherapy With or Without Maintenance Sunitinib for Untreated Extensive-Stage Small-Cell Lung Cancer: A Randomized, Double-Blind, Placebo-Controlled Phase II Study-CALGB 30504 (Alliance).
Ready NE; Pang HH; Gu L; Otterson GA; Thomas SP; Miller AA; Baggstrom M; Masters GA; Graziano SL; Crawford J; Bogart J; Vokes EE
J Clin Oncol; 2015 May; 33(15):1660-5. PubMed ID: 25732163
[TBL] [Abstract][Full Text] [Related]
11. Phase II trial of nanoparticle albumin-bound paclitaxel, carboplatin, and bevacizumab in first-line patients with advanced nonsquamous non-small cell lung cancer.
Reynolds C; Barrera D; Jotte R; Spira AI; Weissman C; Boehm KA; Pritchard S; Asmar L
J Thorac Oncol; 2009 Dec; 4(12):1537-43. PubMed ID: 19887966
[TBL] [Abstract][Full Text] [Related]
12. Phase II trial of irinotecan, paclitaxel and carboplatin in patients with previously untreated Stage IIIB/IV nonsmall cell lung carcinoma.
Socinski MA; Sandler AB; Israel VK; Gillenwater HH; Miller LL; Locker PK; Antonellini A; Elfring GL; Natale RB
Cancer; 2002 Oct; 95(7):1520-7. PubMed ID: 12237921
[TBL] [Abstract][Full Text] [Related]
13. Docetaxel-carboplatin chemotherapy combined with cetuximab in patients with locally advanced or metastatic non small-cell lung cancer (NSCLC)--results of the nonrandomised phase II study TaxErb.
Fischer JR; Griesinger F; Fink T; Salm T; Marseille A; Wolf M
Lung Cancer; 2012 Mar; 75(3):348-52. PubMed ID: 21908069
[TBL] [Abstract][Full Text] [Related]
14. FDA drug approval summary: bevacizumab (Avastin) plus Carboplatin and Paclitaxel as first-line treatment of advanced/metastatic recurrent nonsquamous non-small cell lung cancer.
Cohen MH; Gootenberg J; Keegan P; Pazdur R
Oncologist; 2007 Jun; 12(6):713-8. PubMed ID: 17602060
[TBL] [Abstract][Full Text] [Related]
15. Second-line weekly paclitaxel in resistant or relapsed non-small cell lung cancer treated with docetaxel and carboplatin: a multi-center phase II study.
Ichikawa M; Suzuki R; Kataoka K; Noda Y; Shindoh J; Matsumoto S; Tanikawa Y; Suzuki K; Baba K; Shindo Y; Kondo M; Imaizumi K; Kume H; Hasegawa Y; Takagi K; Taniguchi H
Lung Cancer; 2010 Sep; 69(3):319-22. PubMed ID: 20053476
[TBL] [Abstract][Full Text] [Related]
16. Bevacizumab maintenance in patients with advanced non-small-cell lung cancer, clinical patterns, and outcomes in the Eastern Cooperative Oncology Group 4599 Study: results of an exploratory analysis.
Lopez-Chavez A; Young T; Fages S; Leon L; Schiller JH; Dowlati A; Brahmer JR; Johnson DH; Sandler A
J Thorac Oncol; 2012 Nov; 7(11):1707-12. PubMed ID: 23059774
[TBL] [Abstract][Full Text] [Related]
17. Results of paclitaxel (day 1 and 8) and carboplatin given on every three weeks in advanced (stage III-IV) non-small cell lung cancer.
Yumuk PF; Turhal NS; Gumus M; Hatabay NF; Turken O; Ozkan A; Salepci T; Aliustaoglu M; Ahiskali R
BMC Cancer; 2005 Jan; 5():10. PubMed ID: 15667664
[TBL] [Abstract][Full Text] [Related]
18. Phase I/II trial of neoadjuvant sunitinib administered with weekly paclitaxel/carboplatin in patients with locally advanced triple-negative breast cancer.
Yardley DA; Shipley DL; Peacock NW; Shastry M; Midha R; Priego VM; Hainsworth JD
Breast Cancer Res Treat; 2015 Aug; 152(3):557-67. PubMed ID: 26155975
[TBL] [Abstract][Full Text] [Related]
19. A phase II study of concurrent carboplatin and paclitaxel and thoracic radiotherapy for completely resected stage II and IIIA non-small cell lung cancer.
Feigenberg SJ; Hanlon AL; Langer C; Goldberg M; Nicolaou N; Millenson M; Coia LR; Lanciano R; Movsas B
J Thorac Oncol; 2007 Apr; 2(4):287-92. PubMed ID: 17409799
[TBL] [Abstract][Full Text] [Related]
20. Induction chemotherapy with paclitaxel plus carboplatin followed by paclitaxel with concurrent radiotherapy in stage IIIB non-small-cell lung cancer (NSCLC) patients: a phase II trial.
Pallarés C; Capdevila J; Paredes A; Farré N; Ciria JP; Membrive I; Basterrechea L; Gomez-Segura G; Barnadas A
Lung Cancer; 2007 Nov; 58(2):238-45. PubMed ID: 17658655
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]